SBIR-STTR Award

To address the need for improved treatment protocols that can ensure a higher rate of recovery from traumatic eye injury, i2C Solutions in collaboration with Oxygen Emulsion Company (OE Co), LLC, propose to develop a new topical therapy for ocular trauma that derives from a wound-healing technology originally funded by DARPA. The treatment involves application of a liquid peruorodecalin (PFD)/O2 emulsion to the eye. The anticipated therapeutic benefits include up-regulation in collagen I expression, a correlated increase in re-generation of damaged sclera, conjunctiva, corneal epithelium, and ocular adnexa dermal tissues, and acceleration of ocular wound healing.

To address the need for improved treatment protocols that can ensure a higher rate of recovery from traumatic eye injury, i2C Solutions proposes to continue developing a new topical therapy for ocular trauma that derives from a wound-healing technology originally funded by DARPA. The treatment involves application of a supersaturated oxygen emulsion (SOE) to the eye. During Phase II, the emulsion will be re-formulated to meet military product requirements. Afterwards, the team will perform a more extensive series of laboratory investigations using in vitro and ex vivo models with close cooperation with military medical personnel and stakeholders in order to establish clearly the underlying science (e.g., efficacy in preserving damaged eye tissue and promoting general healing) and to determine optimal formulation and dosage. The SOE formulation and applicator/eye patch will be further developed for manufacturability and field use, and best pathways for clinical trials and product certification in Phase III will be identified from discussions with USAMRMC and FDA stakeholders.